Codeine Cough Syrup Dosing
For chronic bronchitis, codeine is recommended at standard doses for short-term symptomatic cough relief, but it should NOT be used for upper respiratory infections or in children under 12 years of age due to lack of efficacy and serious safety concerns.
Adult Dosing
Standard dose: 10 mL (containing codeine) every 4 hours, not exceeding 6 doses in 24 hours 1. In clinical practice, typical daily doses range from 30-60 mg/day for chronic cough management 2, 3.
When to Use Codeine:
- Chronic bronchitis: Grade B recommendation for short-term symptomatic relief 4, 5
- Treatment duration typically 2-4 weeks, though real-world data shows 14-60 days median duration 2
- Codeine demonstrated superior efficacy compared to levodropropizine, with VAS score improvements of 35.11 vs 19.77 points 3
When NOT to Use Codeine:
- Upper respiratory infections/common cold: Grade D recommendation - no benefit demonstrated 4, 5
- Persistent cough with excessive phlegm without evaluation 1
- Chronic pulmonary disease or shortness of breath without physician guidance 1
- Known CYP2D6 ultra-rapid metabolizers (3% of Northern European population) - risk of serious respiratory depression 6
Pediatric Dosing and Critical Restrictions
Children 6 to under 12 years: 5 mL every 4 hours, not exceeding 6 doses in 24 hours 1
Children under 6 years: Consult a doctor 1
European-Wide Restrictions:
Codeine is contraindicated in children 0-12 years for cough and cold due to risk of serious respiratory side effects 6. This reflects pharmacogenetic variability in CYP2D6 metabolism leading to unpredictable morphine conversion and potential fatal respiratory depression.
Evidence shows codeine is no more effective than placebo for acute cough in children 7, making the risk-benefit ratio unacceptable in this population.
Key Safety Considerations
Common Side Effects:
- Drowsiness, constipation, headaches (more frequent than alternative antitussives) 3
- Documented adverse events in 7.8% of patients in real-world practice 2
- May cause or aggravate constipation 1
Monitoring Requirements:
- Stop use if symptoms persist beyond 7 days or are accompanied by fever, rash, or persistent headache 1
- Individual responses vary significantly; careful monitoring essential 3
- Risk of dependency with prolonged use - 14% of patients prescribed >8 weeks in clinical practice 2
Contraindications:
- Pregnancy/breastfeeding: consult healthcare professional 1
- CYP2D6 ultra-rapid metabolizers at any age 6
- Concurrent use of other sedating medications requires physician oversight 1
Clinical Algorithm
- Identify cough etiology: Chronic bronchitis (use codeine) vs URI/common cold (do NOT use codeine)
- Age assessment: Adults and children ≥12 years only for therapeutic use
- Exclude contraindications: Ultra-rapid metabolizers, respiratory compromise, pregnancy
- Initiate standard dosing: Adults 10 mL q4h; adjust based on response
- Time-limit therapy: 2-4 weeks maximum; reassess if symptoms persist beyond 7 days
- Monitor for adverse effects: Constipation, sedation, respiratory depression
Important Caveats
The evidence quality for codeine efficacy is only fair with intermediate benefit 4, 5, yet prescription rates remain high in clinical practice 2. This reflects an unmet clinical need rather than robust evidence. The 2006 ACCP guidelines represent the most authoritative guidance, though they acknowledge limited evidence quality. Recent research confirms modest efficacy but emphasizes safety concerns, particularly in vulnerable populations 6, 3, 7.